Roche's Wilserdly Receives US FDA Approval for Advanced Breast Cancer
Roche receives US FDA approval for Wilserdly in combination with everolimus for adults with ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer.
ESR1-mutated Breast Cancer | 18/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy